US › Healthcare

NewcelX Ltd. (NCEL)

US · Healthcare · Biotechnology

$3.45+0.88%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Net profit

$4.3M

Profit YoY

+95418.0%

EPS

$-1.05

EPS estimate

$0.00

Key statistics

Market cap

$18.8M

Forward P/E

0.0

P/B

2.59

Book value

$1.51

EPS (TTM)

$-2.16

52-week high

$28.03

52-week low

$1.83

50-day MA

$3.56

200-day MA

$3.86

Beta

0.57

Analyst view

with an average price target of $23.00.

Shareholding

Insiders

68.06%

Institutions

1.14%

Largest institutional holders

Fund	Stake
UBS Group AG	0.01%
Tower Research Capital LLC	0.00%
CoreCap Advisors, LLC	0.00%
Caitong International Asset Management Co., Limited.	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for NewcelX Ltd. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.